Affymetrix Inc. of Santa Clara, Calif., has signed an agreement with Medical Prognosis Institute A/S of Horsholm, Denmark, to develop and commercialize microarray-based drug-sensitivity prediction and prognostic products for patients with cancer. The agreement grants the institute nonexclusive access to the company’s microarray technology. The institute hopes to obtain regulatory clearance and to achieve commercialization within two years.
The technology also is being used by Wellcome Trust Sanger Institute of Hinxton, UK, to catalog the structural genomic changes in nearly 800 cancer cell lines. The information will enable the institute to advance understanding of the disease and may assist with diagnoses and treatment options in the future.